Abstract
Vitamin D deficiency is a well-established risk factor for bone disease. Emerging data suggest a pleiotropic role of this agent in a variety of functions in humans. Epidemiological studies indicate an inverse association between vitamin D deficiency and the prevalence of cardiovascular disease (CVD), as well as individual cardiometabolic risk factors, such as hypertension, diabetes, dyslipidemia and the metabolic syndrome. Moreover, vitamin D deficiency has been implicated in the atherosclerotic process.
This review considers current data regarding the role of vitamin D deficiency in the development of CVD and addresses the effect of supplementation on cardiovascular outcomes.
Keywords: Vitamin D, cardiovascular disease, hypertension, diabetes mellitus, metabolic syndrome
Current Vascular Pharmacology
Title: Vitamin D and Cardiovascular Disease: A Novel Agent for Reducing Cardiovascular Risk?
Volume: 8 Issue: 5
Author(s): Panagiotis Anagnostis, Vasilios G. Athyros, Fotini Adamidou, Matilda Florentin and Asterios Karagiannis
Affiliation:
Keywords: Vitamin D, cardiovascular disease, hypertension, diabetes mellitus, metabolic syndrome
Abstract: Vitamin D deficiency is a well-established risk factor for bone disease. Emerging data suggest a pleiotropic role of this agent in a variety of functions in humans. Epidemiological studies indicate an inverse association between vitamin D deficiency and the prevalence of cardiovascular disease (CVD), as well as individual cardiometabolic risk factors, such as hypertension, diabetes, dyslipidemia and the metabolic syndrome. Moreover, vitamin D deficiency has been implicated in the atherosclerotic process.
This review considers current data regarding the role of vitamin D deficiency in the development of CVD and addresses the effect of supplementation on cardiovascular outcomes.
Export Options
About this article
Cite this article as:
Anagnostis Panagiotis, G. Athyros Vasilios, Adamidou Fotini, Florentin Matilda and Karagiannis Asterios, Vitamin D and Cardiovascular Disease: A Novel Agent for Reducing Cardiovascular Risk?, Current Vascular Pharmacology 2010; 8 (5) . https://dx.doi.org/10.2174/157016110792006978
DOI https://dx.doi.org/10.2174/157016110792006978 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Appropriate Application of Evidence to the Care of Elderly Patients with Diabetes
Current Diabetes Reviews Reducing the Risk of Type 2 Diabetes - Early Identification of High-Risk Individuals and Treatment with Acarbose
Current Diabetes Reviews Editorial (Thematic Issue):Inflammation and Atherosclerosis: The Role of Novel Biomarkers (Part-I)
Current Medicinal Chemistry Association Between Pulmonary Hypertension and Transcatheter Aortic Valve Replacement: Analysis of a Nationwide Inpatient Sample Database
Reviews on Recent Clinical Trials The Therapeutic Implications of Renin-Angiotensin System Blockade in Diabetic Retinopathy
Current Pharmaceutical Biotechnology Novel Biomarkers Assessing Renal Function in Heart Failure: Relation to Inflammatory Status and Cardiac Remodelling
Current Medicinal Chemistry New Developments on Thromboxane Modulators
Mini-Reviews in Medicinal Chemistry Threes Company: Regulation of Cell Fate by Statins
Current Drug Targets - Cardiovascular & Hematological Disorders Arterial Stiffness and Cardiovascular Drugs
Current Pharmaceutical Design The Central Role of Angiotensin I-Converting Enzyme in Vertebrate Pathophysiology
Current Topics in Medicinal Chemistry Clinical Science of Calcium Channel Blocker to Inhibit Hypertensive Vascular Injury
Current Hypertension Reviews Antiinflammatory Activities of CGRP Modulating Innate Immune Responses in Health and Disease
Current Protein & Peptide Science Early Diagnosis of Alzheimers Disease: Is MCI Too Late?
Current Alzheimer Research Evaluation of In Vivo Efficacy of Aqueous Extract of Aerial Parts of Cynodon dactylon in Rats with Simultaneous Type 2 Diabetes and Hypertension
Current Bioactive Compounds Endothelin-1 Impairs Retrograde Axonal Transport and Leads to Axonal Injury in Rat Optic Nerve
Current Neurovascular Research Nutriproteomics – Linking Proteomics Variation with Personalized Nutrition
Current Pharmacogenomics and Personalized Medicine Healthcare Expenditures Related to BMI and Physical Activity Among Diabetic Older People: Cross-sectional Analysis of Sabe Study
Current Diabetes Reviews Homologation: A Versatile Molecular Modification Strategy to Drug Discovery
Current Topics in Medicinal Chemistry Lipid Mediator Profiling in Pulmonary Disease
Current Pharmaceutical Biotechnology Correlation of Salusin Beta with hs-CRP and ADMA in Hypertensive Children and Adolescents
Current Pharmaceutical Design